Strut Health: Clinical Gaps, Limitations, and What They Don't Tell You

What Strut Health Actually Offers

Strut Health provides compounded prescription medications through an asynchronous telehealth model. Patients complete online questionnaires, upload photos, and receive prescriptions from licensed providers without a synchronous video or phone visit. The pharmacy compounds combination formulations, often mixing active ingredients like finasteride, minoxidil, tretinoin, and others into single topical preparations.

This model is legal. Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by licensed pharmacies with valid prescriptions. The FDA has stated clearly that "compounded drugs are not FDA-approved" and that the agency "does not verify the safety or effectiveness of compounded drugs" [1]. That distinction matters. Every formulation Strut dispenses sits outside the evidence framework that FDA-approved drugs must satisfy through Phase III trials.

The compounding model allows creative combinations. But creative is not the same as clinically validated. A formulation containing finasteride 0.1% plus minoxidil 5% plus tretinoin 0.01% in a single topical vehicle has not been tested as that specific combination in a randomized controlled trial with adequate power and follow-up duration [2].

The Evidence Gap in Compounded Hair Loss Formulations

Strut's hair loss products represent its most visible category. The typical offering combines topical finasteride with minoxidil, sometimes adding tretinoin, dutasteride, or other agents. Each ingredient has supporting evidence individually. Oral finasteride 1 mg daily demonstrated hair count increases in 83% of men over two years in its key trial [3]. Topical minoxidil 5% showed superior regrowth versus 2% in the landmark Price et al. study [4]. These are well-established therapies.

The gap emerges at the combination level. When Strut compounds finasteride into a topical with minoxidil, the resulting product is pharmacokinetically distinct from either agent studied alone. Topical finasteride bioavailability, penetration depth, and systemic absorption vary based on vehicle composition, concentration, and co-administered ingredients [5]. A 2022 systematic review in the Journal of the American Academy of Dermatology found that topical finasteride concentrations in published studies ranged from 0.005% to 1%, with "substantial heterogeneity in vehicle formulation, application frequency, and outcome measures" making cross-study comparison difficult [6].

Strut does not publish what concentrations they use in their compounded formulas on their website with full transparency. Patients cannot easily compare their prescribed formulation against peer-reviewed protocols. Dr. Antonella Tosti, a professor of dermatology at the University of Miami, has noted that "the lack of standardization in compounded topical finasteride formulations makes it impossible to generalize efficacy claims from one product to another" [7].

This is not a condemnation of compounding. It is a factual limitation that patients deserve to understand before subscribing.

Asynchronous Prescribing and Diagnostic Limitations

Strut's consultation model relies on questionnaires and uploaded photographs. No dermatoscopy. No scalp biopsy option. No blood work ordered as part of the initial evaluation. For straightforward male androgenetic alopecia in a 30-year-old with a clear Norwood pattern, this approach may be adequate. For other presentations, it is not.

The American Academy of Dermatology's guidelines on alopecia emphasize that "a thorough history and physical examination, including pull test and dermoscopy, are the cornerstones of hair loss diagnosis" [8]. Telogen effluvium, alopecia areata, frontal fibrosing alopecia, and scarring alopecias can mimic androgenetic alopecia in photographs. Misdiagnosis leads to wrong treatment. Wrong treatment leads to disease progression that might have been preventable.

A 2021 study in JAMA Dermatology evaluating diagnostic accuracy in teledermatology found that photo-based assessments had a concordance rate of 78.5% with in-person dermatologic diagnosis for hair disorders, dropping to 64.2% for inflammatory and scarring subtypes [9]. That means roughly one in three inflammatory hair loss cases could be misclassified in a photo-only model.

Blood work matters too. The Endocrine Society recommends evaluating thyroid function, ferritin, and androgen levels in women presenting with hair loss [10]. Iron deficiency (ferritin <30 ng/mL) is present in up to 72% of women with diffuse hair loss according to a study in the Journal of the European Academy of Dermatology and Venereology [11]. Strut's model does not include laboratory evaluation, meaning treatable underlying conditions may go undetected while the patient applies topical medications to a symptom rather than a cause.

Sexual Health Prescribing: What Gets Missed

Strut also offers treatments for erectile dysfunction and premature ejaculation, typically compounded combinations that may include sildenafil or tadalafil with other agents. The clinical concern here is similar: individual ingredients have strong evidence, but the specific combinations and the prescribing pathway deserve scrutiny.

The American Urological Association guidelines on erectile dysfunction state that "a focused history and physical examination are essential" and that ED can be "a sentinel marker for cardiovascular disease" [12]. A 2018 meta-analysis in the European Heart Journal found that men with ED had a 43% increased risk of cardiovascular events (HR 1.43, 95% CI 1.20 to 1.69) [13]. Prescribing PDE5 inhibitors without cardiovascular risk stratification, medication reconciliation for nitrate use, and blood pressure assessment carries real clinical risk.

Strut's asynchronous model collects medication history via questionnaire. It relies on patient self-reporting for contraindications. This is standard practice across DTC telehealth platforms, not unique to Strut. But "standard across the industry" and "clinically adequate" are different standards. Dr. Arthur Burnett, a professor of urology at Johns Hopkins, has emphasized that "erectile dysfunction should prompt cardiovascular evaluation, not just symptomatic treatment with a prescription" [14].

Skin Care Formulations and Retinoid Considerations

Strut's anti-aging and acne lines feature compounded tretinoin combinations, sometimes including hydroquinone, niacinamide, or hyaluronic acid. Tretinoin has decades of evidence supporting its use in photoaging and acne [15]. The concern is not the active ingredient but the prescribing context.

Hydroquinone, commonly included in skin-lightening compounded formulas, has a specific safety profile that warrants monitoring. The FDA proposed a ban on over-the-counter hydroquinone in 2006, and although prescription compounding remains legal, prolonged use above 4% concentration or beyond 12 weeks increases the risk of ochronosis, a paradoxical darkening that can be permanent [16]. The American Academy of Dermatology recommends periodic in-person skin checks during hydroquinone therapy.

An asynchronous photo review may not detect early ochronosis changes, subtle contact dermatitis, or post-inflammatory hyperpigmentation patterns that require treatment modification. The question is not whether Strut's providers are competent. The question is whether the delivery model provides sufficient clinical feedback loops for medications that require visual monitoring.

Pricing Transparency and Subscription Lock-In

Strut operates on a subscription model. Monthly charges auto-renew. This is common in DTC telehealth, but the pricing structure deserves examination relative to alternatives.

Generic finasteride 1 mg (oral) costs approximately $3 to $10 per month through GoodRx at retail pharmacies [17]. Generic topical minoxidil 5% is available over the counter for roughly $8 to $15 monthly. A Strut compounded combination typically runs $35 to $85 per month depending on the formulation, which means the convenience premium ranges from 200% to 600% over acquiring each ingredient separately.

That premium might be justified if the combination offered proven superiority. But no head-to-head trial has compared a compounded finasteride-minoxidil topical against using both agents separately in their standard FDA-approved forms. Patients should understand what they are paying for: convenience and a single-application routine, not clinically demonstrated superiority.

Regulatory Oversight and Quality Considerations

Compounding pharmacies are regulated primarily at the state level, with FDA oversight limited to specific enforcement actions. The FDA's 2023 report on compounding noted that inspections of 503A pharmacies identified "insanitary conditions, potency failures, or sterility concerns" in 28% of facilities inspected [18]. This is an industry-wide statistic, not specific to Strut's pharmacy. But it underscores that compounded medications carry manufacturing variability risk that commercially manufactured FDA-approved drugs do not.

The United States Pharmacopeia (USP) sets standards for compounding in chapters <795> (nonsterile) and <797> (sterile). Compliance is not uniformly verified across all state boards of pharmacy. Patients using any compounding service, including Strut, should verify that the dispensing pharmacy holds current state licensure and PCAB accreditation or equivalent third-party certification [19].

How Strut Compares to Specialist-Led Care

A board-certified dermatologist managing hair loss will typically perform dermoscopy, may order a scalp biopsy for unclear cases, will check labs for hormonal and nutritional contributors, can prescribe FDA-approved oral finasteride or dutasteride, can offer intralesional treatments or platelet-rich plasma, and will monitor for side effects with scheduled follow-up visits.

A board-certified urologist managing ED will perform a physical exam, may order hormonal panels (total testosterone, free testosterone, prolactin, TSH), will stratify cardiovascular risk, can prescribe FDA-approved PDE5 inhibitors at standard doses, and can offer penile duplex ultrasound or referral for refractory cases.

Strut provides none of these services. It provides medication access. That is a real value for patients who have already been diagnosed, who understand their condition, and who want a convenient refill pathway. It is a less appropriate entry point for patients with new, undiagnosed, or complex presentations.

The Bottom Line on Legitimacy

Strut is a licensed, legal telehealth company. It is not a scam. It fills real prescriptions through a real compounding pharmacy. The providers hold valid medical licenses. The medications contain actual active pharmaceutical ingredients.

The limitations are structural, not fraudulent. Photo-based diagnosis misses conditions that require hands-on evaluation. Compounded formulations lack the clinical trial evidence that FDA-approved drugs carry. Subscription pricing exceeds the cost of equivalent generic medications purchased separately. Follow-up protocols do not mandate the monitoring that dermatology and urology guidelines recommend.

Patients who choose Strut should do so with clear eyes: they are trading diagnostic depth and evidence certainty for convenience and combination simplicity. For a 28-year-old man with obvious vertex thinning who has already seen a dermatologist and confirmed androgenetic alopecia, Strut may be a perfectly reasonable refill channel. For a 45-year-old woman with new diffuse hair loss and fatigue, skipping the lab work and in-person evaluation to go straight to a compounded topical is a clinical gamble with identifiable downside risk.